<DOC>
	<DOC>NCT03020004</DOC>
	<brief_summary>The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.</brief_summary>
	<brief_title>Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing and able to provide written informed consent Chronic HCV infection (≥ 6 months) ; Positive HCV antibody Serum HCV RNA of ≥ 1 × 104 IU/mL Hepatitis C virus GT1 Never received priortreatment for HCV with interferon, RBV, or other directacting or hosttargeting antivirals for HCV The liver biopsy methods in the protocol (noncirrhosis is defined as: Metavir score ˂ 4), or as determined by Fibroscan defined as: ˂ 14.6 kPa. Patients who have not obtained a liver biopsy or Fibroscan in the last 1 years will have a study related Fibroscan performed in order to confirm the diagnosis Others as specified in the detailed protocol Patients with Fibroscan detection value &gt; 12.9 kPa, or histologic examination for liver cirrhosis patients Presence or history of nonhepatitis C chronic liver disease, including but not limited to, autoimmune hepatitis, α1antitrypsin deficiency, C282Y homozygous hemochromatosis, Wilson's disease, drug or toxininduced liver disease, alcoholrelated liver disease, primary biliary cirrhosis, sclerosing cholangitis, and porphyria cutanea tarda causing liver pathology or requiring phlebotomy Patients with a history of liver cell cancer, screening before or screening suspected hepatocellular carcinoma (HCC) patients, or imaging studies found suspicious nodules, or AFP &gt; 50 ng/mL Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody or HIV antibody at screening Others as specified in the detailed protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Danoprevir</keyword>
	<keyword>SVR12</keyword>
	<keyword>Chinese HCV G1</keyword>
	<keyword>non-cirrhotic</keyword>
</DOC>